The mission of the Mayo Clinic Cancer Center is to promote and facilitate basic and clinical research on the incidence, etiology, and progression of cancer, and then through education and direct application of the results of such research, translate the discoveries into improved methods for cancer prevention, detection, diagnosis, prognosis and therapy. The ultimate goal is to relieve the burdens of illness in patients with cancer. Accordingly, Mayo Clinic Cancer Center research is broad and interdisciplinary, but highly cancer focused. Professional and lay education activities are excellent and expansive, and clinical and psychosocial care of patients are of the highest quality and humanistic. These aggregate characteristics form the basis for our request for CCSG support and to be designated by the National Cancer Institute as a Comprehensive Cancer Center. The scientific objectives will be achieved by seven established programs of the MCCC. These programs are assigned to three portfolios each managed by an Associate Director, namely: Basic Science (Immunology, Developmental Therapeutics and Cancer Genetics Program); Clinical and Translational Research Portfolio (Clinical and Translational Research, Prostate Cancer, and Imaging Programs); and a Population Sciences Portfolio with a single Program in Genetic Epidemiology, Prevention and Control. There is a single Developing Program for Breast Cancer Cell Biology. Research in these programs will be facilitated by nine shared resources for Statistics and Support Services, Pharmacy, Tissue Acquisition, Pharmacology, Gene Discovery, Cytogenetics, Molecular Biology, Protein Chemistry, and Flow Cytometry and Optical Morphology). An extensive non-CCSG funded Education Program rounds out the CCSG request.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA015083-25S3
Application #
6153783
Study Section
Subcommittee G - Education (NCI)
Project Start
1988-03-01
Project End
2002-02-28
Budget Start
1999-05-27
Budget End
2000-02-29
Support Year
25
Fiscal Year
1999
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
City
Rochester
State
MN
Country
United States
Zip Code
55905
Nowsheen, Somaira; Aziz, Khaled; Aziz, Asef et al. (2018) L3MBTL2 orchestrates ubiquitin signalling by dictating the sequential recruitment of RNF8 and RNF168 after DNA damage. Nat Cell Biol 20:455-464
Razidlo, Gina L; Burton, Kevin M; McNiven, Mark A (2018) Interleukin-6 promotes pancreatic cancer cell migration by rapidly activating the small GTPase CDC42. J Biol Chem 293:11143-11153
Wu, Dongyan; Yang, Haitao; Winham, Stacey J et al. (2018) Mediation analysis of alcohol consumption, DNA methylation, and epithelial ovarian cancer. J Hum Genet 63:339-348
Leon-Ferre, Roberto A; Polley, Mei-Yin; Liu, Heshan et al. (2018) Impact of histopathology, tumor-infiltrating lymphocytes, and adjuvant chemotherapy on prognosis of triple-negative breast cancer. Breast Cancer Res Treat 167:89-99
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551

Showing the most recent 10 out of 1129 publications